Compare Mesoblast Limited (MESO) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs ABRDN Physical Gold Shares ETF — how do they compare? Mesoblast Limited trades at $14.12 (market cap $1.75B), while ABRDN Physical Gold Shares ETF trades at $39.85 (market cap $7.03B). The key difference: ABRDN Physical Gold Shares ETF is far larger — about 4× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 2,350,550). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| MESO | SGOL | |
|---|---|---|
Market Cap | $1.75B | $7.03B |
Volume | 239,027 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $20.96 | $51.41 |
52-Week Low | $13.19 | $37.54 |
Typical Hold Time | 14 Days | 57 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
SGOL is trading at $39.02, down 1.66% with bearish technical signals dominating across moving averages and oscillators. The stock faces significant resistance at current levels with all support and resistance clustered around $39. Recent market sentiment reflects pressure from rising Treasury yields and Federal Reserve policy uncertainty, though some technical indicators like the 12-day RSI at 24.81 suggest potential oversold conditions.
The outlook remains challenging with persistent bearish momentum, though the deeply oversold RSI reading indicates potential for near-term stabilization. Investment opportunities exist for contrarian investors seeking gold exposure amid inflation concerns, while risks include continued pressure from rising interest rates and dollar strength that could push prices lower.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
